Literature DB >> 26978707

Full-Support LVAD Implantation in a C-Pulse Heart Assist System Recipient with Deteriorating Chronic Heart Failure: Is It Feasible and Safe?

Mohamed Zeriouh1, Anton Sabashnikov, Christopher T Bowles, Alexander Weymann, Ali Ghodsizad, Prashant N Mohite, Nikhil P Patil, André R Simon, Aron-Frederik Popov.   

Abstract

Heart failure is a progressive disease with limited treatment options. The C-Pulse Heart Assist System (Eden Prairie, MN) is an extravascular, diastolic counterpulsation circulatory support device for patients with refractory NHYA Class III/ambulatory class IV heart failure. It comprises a balloon-cuff which is implanted around the ascending aorta that is synchronised to inflate during ventricular diastole. The system eliminates the need for systemic anticoagulation and significantly reduces the risk of bleeding and overcomes the problem of device thrombosis. However, clinical efficacy is dependent on maintenance of residual myocardial function. We describe a case of a patient who presented with ischemic cardiomyopathy in end-stage heart failure and received the C-Pulse System. Due to deterioration in cardiac function, the system had to be upgraded to a full-support left ventricular assist device (LVAD) after 4 months. However, the aorta ascendens was short and the outflow graft of the HeartWare LVAD had to be anastomosed to the cuff balloon region of the aorta. Our experience showed in this case that the inflatable cuff action did not compromise the structural integrity of the aortic wall.

Entities:  

Mesh:

Year:  2016        PMID: 26978707     DOI: 10.1097/MAT.0000000000000365

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  1 in total

1.  Effects of an intra-ventricular assist device on the stroke volume of failing ventricle: Analysis of a mock circulatory system.

Authors:  Shidong Zhu; Lin Luo; Bibo Yang; Kai Ni; Qian Zhou; Xinghui Li; Xiaohao Wang
Journal:  Technol Health Care       Date:  2018       Impact factor: 1.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.